CA
NZ
UK
AU
IND
US
• The company secured dual positive CHMP opinions for RINVOQ in severe alopecia areata and non-segmental vitiligo.
• First-quarter earnings per share reached $2.70 on revenue of $24.06 billion, up 9.9% year over year.
• The company reported securing lower raw material prices from suppliers to stay competitive in the weight-loss drug market.
• The stock remains roughly 68% below its May registered-direct offering price of $20.30.
• Shared umbrella with BLKIF: IAACF trades under the same iShares IV PLC structure as BLKIF, though the two represent distinct underlying funds.
• Four distinct funds: GDX, GDXJ, RING and SIL each provide exposure to precious metals mining, but with different company size and geographic focus.
• Global reach: Defense themed funds spanning both broad global exposure and regional European focus posted gains in the same session.
• Precious metals lead: Gold and silver mining ETFs, including GDX, GDXJ, RING and SIL, posted some of the day's strongest gains.
• Bullion driven rally: Strength in gold prices has translated into amplified gains across mining equity funds.
• Strong sector move: The iShares U.S. Medical Devices ETF (NYSEARCA: IHI) rose 3.80% to close at $51.88.
Please wait processing your request...